[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528389":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":29,"locations":38,"responsibleParty":57,"collaborators":59,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Feb 2022",null,"This cohort study assessed outpatient Veterans with risk factors for severe COVID-19 who tested positive for SARS-CoV-2 during January and February 2022.\n\nThe purpose is to describe factors associated with receipt of outpatient COVID-19 pharmacotherapies in the Veterans Affairs (VA) health care system.",{"label":13,"type":10,"description":14,"interventionNames":10},"Nonhospitalized Veterans in VHA at risk for SARS-CoV-2 Jan-Jul 2022","Three retrospective target trial emulation studies comparing matched cohorts of nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir- ritonavir versus molnupiravir.\n\nThe purpose is to measure the effectiveness of nirmatrelvir-ritonavir and molnupiravir for outpatient treatment of COVID-19.",{"label":16,"type":10,"description":17,"interventionNames":10},"Outpatient Veterans who tested positive for SARS-CoV-2 from Jan 2022 through Jan 2023","This cohort study evaluated nonhospitalized Veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases.\n\nThe purpose is to analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA).",{"label":19,"type":10,"description":20,"interventionNames":10},"Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Jul 2022","Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment.\n\nThe purpose is to measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing Post COVID conditions.",[22,26],{"name":23,"affiliation":24,"role":25},"Kristina L Bajema, MD","VA Portland Health Care System, Portland, OR","STUDY_CHAIR",{"name":27,"affiliation":28,"role":25},"George N. Ioannou, MD MS","VA Puget Sound Health Care System Seattle Division, Seattle, WA",[30,34],{"name":23,"role":31,"phone":32,"phoneExt":10,"email":33},"CONTACT","(503) 220-8262","Kristina.Bajema@va.gov",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"George N Ioannou, MD MS","(206) 277-3136","George.Ioannou@va.gov",[39],{"facility":24,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Portland","Oregon","97207-2964","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-122.67621,45.52345,{"lat":50,"lon":49},[53,55,56],{"name":23,"role":31,"phone":54,"phoneExt":10,"email":33},"503-220-8262",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},{"name":23,"role":25,"phone":10,"phoneExt":10,"email":10},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[60,62],{"name":61,"class":6},"Biomedical Advanced Research and Development Authority",{"name":63,"class":6},"Food and Drug Administration (FDA)","100528389","clinical-outcomes-and-pharmacotherapy-effectiveness-in-the-va-health-care-system-cope-va-100528389",false,"NCT06160128","Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)","CSP #2038 - COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System (COPE-VA)","COPE-VA","Inclusion Criteria:\n\nPhase 1:\n\n\\- Veterans aged 18 years with a laboratory-confirmed positive test for SARS-CoV-2 or a diagnosis of COVID-19 documented at any time since the beginning of the pandemic in January 2020 to present.\n\nPhase 2:\n\n* All Veterans aged 18 years alive and in VHA care as of January 2018.\n* Specific exclusion\u002Finclusion criteria and observation periods will be further defined for each sub-study (See outcomes\u002Fpublications).\n\nExclusion Criteria:\n\n* VA employees who are not enrollees",true,"ALL","18 Years",{"count":76,"type":77},400000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious diseases. This first phase will critically inform feasibility and direction of the second phase, in which the investigators will use target trial emulation design to study the comparative effectiveness of therapies and vaccines for COVID-19, respiratory viruses, including RSV, and influenza, and other infectious diseases.",[81,82,83],"COVID-19, SARS-CoV-2 Infection","RSV","Influenza",[85,86,87,88,82,89,90],"COVID-19","pharmacotherapy effectiveness","SARS-CoV-2","antiviral","influenza","respiratory viruses","2026-02-05",{"date":93,"type":94},"2026-02-10","ACTUAL",{"date":96,"type":94},"2022-09-26",{"date":98,"type":77},"2027-09-30",{"name":5,"class":6},1]